Acute-on-chronic liver failure (ACLF) is characterized by hepatic and extrahepatic organ dysfunction and/or failure and highly activated systemic inflammation. It leads to an accumulation of different metabolites research hub

A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety, and tolerability of VS-01 on top of standard of care, compared to standard of care alone, in adult patients with acute-on-chronic liver failure (ACLF)

This study is looking at a new treatment called VS-01 for adults with a serious liver condition called acute-on-chronic liver failure (ACLF). It compares VS-01 with standard care to see if it's safe and helps improve liver health.